Individually Adapted Therapy Duration for the Treatment of Chronic Hepatitis C Genotype 1 Infection
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Patients with chronic hepatitis C genotype 1 virus infection are usually treated with
Interferon alfa plus Ribavirin over 48 weeks. For some patients this might be too long, for
others too short. An individually adapted therapy length from 24 to 72 weeks will be
determined in dependence of the initial virus load and the time to HCV RNA negativity.
The primary objective is to compare the cumulative rate of the sustained viral response (SVR)
of the patients with the individually adapted therapy duration to the SVR rates of a historic
patient collective under the 48 week standard therapy.